• 1

    Siddiqui AA, Genta RM, Berk SL, 2006. Strongyloidiasis. Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases–Principles, Pathogens and Practice. (Second edition). Philadelphia: Churchill Livingstone, 1274.

  • 2

    Gyorkos TW, Genta RM, Viens P, MacLean JD, 1990. Sero-epidemiology of Strongyloides infection in the southeast Asian refugee population in Canada. Am J Epidemiol 132 :257–264.

    • Search Google Scholar
    • Export Citation
  • 3

    Keiser PB, Nutman TB, 2004. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 17 :208–217.

  • 4

    Pacanowski J, Santos MD, Roux A, Maignan C, Guillot J, Lavarde V, Cornet M, 2005. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am J Trop Med Hyg 73 :122–124.

    • Search Google Scholar
    • Export Citation
  • 5

    Turner SA, Maclean JD, Fleckenstein L, Greenaway C, 2005. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg 73 :911–914.

    • Search Google Scholar
    • Export Citation
  • 6

    Marty FM, Lowry CM, Rodriguez M, Milner DA, Pieciak WS, Sinha A, Fleckenstein L, Baden LR, 2005. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 41 :e5–e8.

    • Search Google Scholar
    • Export Citation
  • 7

    Hauber HP, Galle J, Chiodini PL, Rupp J, Birke R, Vollmer E, Zebel P, Lange C, 2005. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin. Infection 33 :383–386.

    • Search Google Scholar
    • Export Citation
  • 8

    Salluh JI, Feres GA, Velasco E, Holanda GS, Toscano L, Soares M, 2005. Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock. Intensive Care Med 31 :1292.

    • Search Google Scholar
    • Export Citation
  • 9

    Chiodini PL, Reid AJ, Wiselka MJ, Firmin R, Foweraker J, 2000. Parenteral ivermectin in Strongyloides hyperinfection. Lancet 355 :43–44.

    • Search Google Scholar
    • Export Citation
  • 10

    Kitzman D, Wei SY, Fleckenstein L, 2006. Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. J Pharm Biomed Anal 40 :1013–1020.

    • Search Google Scholar
    • Export Citation
  • 11

    Barber S, Bowles V, Lespine A, Alvinerie M, 2003. The comparative serum disposition kinetics of subcutaneous administration of doramectin, ivermectin and moxidectin in the Australian Merino sheep. J Vet Pharmacol Ther 26 :343–348.

    • Search Google Scholar
    • Export Citation
  • 12

    Lim S, Katz K, Krajden S, Fuksa M, Keystone JS, Kain KC, 2004. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 171 :479–484.

    • Search Google Scholar
    • Export Citation
  • 13

    Takayanagui OM, Lofrano MM, Araujo MB, Chimelli L, 1995. Detection of Strongyloides stercoralis in the cerebrospinal fluid of a patient with acquired immunodeficiency syndrome. Neurology 45 :193–194.

    • Search Google Scholar
    • Export Citation
  • 14

    Thomas MC, Costello SA, 1998. Disseminated strongyloidiasis arising from a single dose of dexamethasone before stereotactic radiosurgery. Int J Clin Pract 21 :520–521.

    • Search Google Scholar
    • Export Citation
  • 15

    Boken DJ, Leoni PA, Preheim LC, 1992. Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum. Clin Infect Dis 16 :123–126.

    • Search Google Scholar
    • Export Citation
  • 16

    Kennedy S, Campbell RM, Lawrence JF, Nichol GM, Rao DM, 1989. A case of severe Strongyloides stercoralis infection with jejunal perforation in an Australian ex-prisoner of war. Med J Aust 150 :92–93.

    • Search Google Scholar
    • Export Citation
  • 17

    Tarr PE, Miele PS, Peregoy KS, Smith MA, Neva FA, Lucey DR, 2003. Case report: rectal administration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 68 :453–455.

    • Search Google Scholar
    • Export Citation
  • 18

    Lifschitz A, Virkel G, Pis A, Imperiale F, Sanchez S, Alvarez L, 1999. Ivermectin disposition kinetics after subcutaneous and intramuscular administration of an oil-based formulation to cattle. Vet Parasitol 86 :203–215.

    • Search Google Scholar
    • Export Citation
  • 19

    Klotz U, Ogbuokiri JE, Okonkwo PO, 1990. Ivermectin binds avidly to plasma proteins. Eur J Clin Pharmacol 39 :607–608.

  • 20

    Okonkwo PO, Ogbuokiri JE, Ofoegbu E, Klotz U, 1993. Protein binding and ivermectin estimations in patients with onchocerciasis. Clin Pharmacol Ther 53 :426–430.

    • Search Google Scholar
    • Export Citation
  • 21

    Satou T, Koga M, Koike K, Tada I, Nikaido T, 2001. Nematocidal activities of thiabendazole and ivermectin against the larvae of Strongyloides ratti and S. venezuelensis. Vet Parasitol 99 :311–322.

    • Search Google Scholar
    • Export Citation
  • 22

    Kotze AC, Clifford S, O’ Grady J, Behnke JM, McCarthy JS, 2004. An in vitro larval motility assay to determine anthelmintic sensitivity for human hookworm and Strongyloides species. Am J Trop Med Hyg 71 :608–616.

    • Search Google Scholar
    • Export Citation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Failure of Subcutaneous Ivermectin in Treating Strongyloides Hyperinfection

View More View Less
  • 1 Department of Internal Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, Children’s and Women’s Health Center of British Columbia, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia and Division of Medical Microbiology and Infection Control, Vancouver General Hospital, Vancouver, British Columbia, Canada; Division of Clinical and Administrative Pharmacy, University of Iowa College of Pharmacy, Iowa City, Iowa; Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, Canada
Restricted access

A man with Escherichia coli meningitis and bacteremia, while on dexamethasone, developed Strongyloides hyperinfection syndrome and died despite salvage therapy with subcutaneous ivermectin. We report the first documented total and free levels of subcutaneous ivermectin used for therapy.

Save